Covigilant Research, LLC Clinical Trials Site Management Organization

Covigilant Research, LLC

Committed To Working Together

Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product …,

The second product candidate, GB7208, is currently in IND-enabling studies and is expected to enter the clinic in the second half of 2022. In a BTK-dependent …, The second product candidate, GB7208, is currently in IND-enabling studies and is expected to enter the clinic in the second half of 2022. In a BTK-dependent …, Read More

Scroll to Top